Evidence map›Paper›PMID 38948934›Full record

ArticleDrug testing and analysis2025

Isolation and characterization of synthesis intermediates and side products in hexahydrocannabiphorol.

Willi Schirmer, Ilche Gjuroski, Martina Vermathen, Julien Furrer, Stefan Schürch, Wolfgang Weinmann

Abstract read
In one paragraph

Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Willi SchirmerInstitute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0009-0004-5579-2217
Ilche GjuroskiDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.
Martina VermathenDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-0796-1643
Julien FurrerDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-2096-0618
Stefan SchürchDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-5109-4623
Wolfgang WeinmannInstitute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-8659-1304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After the Swiss ban of hexahydrocannabinol (HHC) in March 2023, other semisynthetic dibenzopyran cannabinoids emerged on the Swiss gray market. Hexahydrocannabiphorol (HHCP) was the most prominent of them due to its potent cannabimimetic effects, as anecdotal reports from recreational users suggest. In October 2023, a class wide ban of dibenzopyran cannabinoids was introduced in Switzerland to prevent new similar substances from entering the drug market. Various vendors in online shops claim that HHCP is made from CBD, even though they possess different alkyl chain lengths. An HHCP sample was analyzed by gas chromatography coupled to mass spectrometry (GC-MS), showing that a mixture of molecules with the same or a similar molecular mass as HHCP was present. Six different substances could be isolated from this sample using column chromatography. Four phenols ((9R)-HHCP, iso-HHCP, cis-HHCP, and abn-HHCP) and two ketones (possible intermediates to (9R)-HHCP and abn-HHCP) were identified by various nuclear magnetic resonance spectroscopy (NMR) techniques. (9S)-HHCP was obtained in an impure fraction. In addition, a fraction was obtained that showed characteristic molecular and fragment ions consistent with bisalkylated products from the synthesis of similar compounds. The presence of abnormal cannabinoids (abn-HHCP) and bisalkylated cannabinoids is a confirmation that this sample was produced purely synthetically as initially suspected, as these compounds have not been reported in Cannabis. Chiral derivatization of the phenols with Mosher acid chlorides showed that only iso-HHCP was present as a scalemic mixture, indicating a good stereocontrol of this synthetic procedure.

Indexed as

CannabinoidsDronabinolIllicit DrugsGas Chromatography-Mass SpectrometryMagnetic Resonance SpectroscopySwitzerlandCannabinoidsDronabinolIllicit Drugscannabishexahydrocannabinol (HHC)hexahydrocannabiphorol (HHCP)isomeric cannabinoidsMosher ester

Identifiers

PMID38948934
PMCPMC11994377

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.